

IN THE CLAIMS:

1.-10. (Canceled)

11. (Currently amended) A method for treating psoriasis in a patient in need thereof comprising the step of administering a topical formulation,

wherein said formulation comprises a psoriasis-treating amount of epidermal growth factor as the sole active agent, and wherein the patient is a human being.

12. (Previously presented) The method according to claim 11, wherein the topical formulation contains EGF in a concentration of 0.01 to 50 micrograms/gram formulation.

13. (Previously presented) The method according to claim 11, wherein the topical formulation contains EGF in a concentration of 0.5 to 20 micrograms EGF/gram formulation.

14. (Canceled)

15. (Currently Amended) ~~A method for treating psoriasis in a patient in need thereof comprising the step of administering a topical formulation,~~ The method according to claim 11, wherein the formulation is a topical cream containing 0.1 to 3% (w/w) of sulfadiazine and 0.5 to 20 micrograms EGF/gram formulation.

16. (Previously presented) The method according to claim 15, wherein the formulation comprises 10µg EGF and 1% (w/w) sulfadiazine.

17.-19. (Canceled)